Keyword: Perjeta

FDA boosts Roche breast cancer hopes with new Kadcyla approval

by Kyle Blankenship

Monday, May 6, 2019

With a new FDA nod in postsurgery patients—and Herceptin biosimilars looming—Roche's Kadcyla has more space to run.

Roche's drugs, new and old, team up for major sales

by Angus Liu

Wednesday, April 17, 2019

Last July, Roche put a halt on U.S. price hikes. But that didn't stop five of its products from topping analysts' estimates by double digits in Q1.

2. Roche

by Angus Liu

Roche grew sales by 7% in 2018, even as biosimilar rivals unleashed damage in Europe. But 2019 will be the moment of truth for the Swiss drugmaker. U.S. copycats to its trio of cancer megablockbusters—Herceptin, Rituxan and Avastin—are expected to arrive.

NICE finally backs Roche's Perjeta in postsurgery breast cancer

by Carly Helfand

Friday, February 15, 2019

Looks like the third time was a charm for Roche’s Perjeta when it comes to postsurgery treatment of HER2-positive breast cancer.

Roche looks at weaker 2019 on biosim attack

by Angus Liu

Thursday, January 31, 2019

Roche expects 2019 sales growth in low- to mid-single digits, compared with 7% in 2018, partially on expected U.S. biosimilar launches.

Roche unveils data for Kadcyla move into early breast cancer

by Eric Sagonowsky

Wednesday, December 5, 2018

With biosim rivals looming, Roche will need its newer meds to step up, and Wednesday's Kadcyla data could give its breast cancer franchise a boost.

1. Roche

by Carly Helfand

Roche

Roche insists its new drugs will outgrow U.S. biosim erosion

by Angus Liu

Wednesday, October 17, 2018

Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.

Can new Kadcyla data soften the blow when Herceptin biosims hit?

by Tracy Staton

Monday, October 15, 2018

Roche is teeing up a new use for its breast cancer drug Kadcyla, hoping to gin up sales as Herceptin biosimilars hurtle toward the U.S. market.

NICE stands firm on 'no' vote for Roche's Perjeta

by Carly Helfand

Monday, August 20, 2018

Back in June, England’s cost watchdog refused to recommend Roche’s Perjeta for postsurgery breast cancer patients. And it’s sticking by that decision.